{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:21:12Z","timestamp":1787667672987,"version":"build-2736575974"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rmed.2024.107766","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T05:11:16Z","timestamp":1724389876000},"page":"107766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Choosing the right biologic treatment for individual patients with severe asthma \u2013 Lessons learnt from Picasso"],"prefix":"10.1016","volume":"234","author":[{"given":"Milan","family":"Terl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-0100","authenticated-orcid":false,"given":"Zuzana","family":"Diamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-4336","authenticated-orcid":false,"given":"Radovan","family":"Kosturiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-2523","authenticated-orcid":false,"given":"Milos","family":"Jesenak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2024.107766_bib1","unstructured":"Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention (2023 Update), (n.d.). http:\/\/www.ginasthma.org (accessed January 3, 2024)."},{"key":"10.1016\/j.rmed.2024.107766_bib2","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jaip.2021.10.032","article-title":"NAEPP guidelines update and GINA 2021\u2014asthma care differences, overlap, and challenges","volume":"10","author":"Chipps","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107766_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/ajrccm.157.3.157315","article-title":"Efficacy and safety of inhaled corticosteroids","volume":"157","author":"Barner","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/thx.2010.153643","article-title":"Biomarkers for the prediction of respiratory disease outcome (U-biopred) consortium, diagnosis and definition of severe refractory asthma: an international consensus statement from the innovative medicine initiative (IMI)","volume":"66","author":"Bel","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107766_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: an EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib9","first-page":"44","volume":"7","author":"St-Germain","year":"2022","journal-title":"US Respir. Pulm. Dis."},{"key":"10.1016\/j.rmed.2024.107766_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib11","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1080\/02770903.2019.1619082","article-title":"Four seasons of Czech asthma study: asthma characteristics and management reality in the Czech Republic","volume":"57","author":"Terl","year":"2020","journal-title":"J. Asthma"},{"key":"10.1016\/j.rmed.2024.107766_bib12","unstructured":"Global Initiative for Asthma, GINA guide for difficult-to-treat and severe asthma in adults and adolescents, (n.d.). http:\/\/www.ginasthma.org (accessed January 3, 2024)."},{"key":"10.1016\/j.rmed.2024.107766_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2016.11.029","article-title":"Changing paradigms in the treatment of severe asthma: the role of biologic therapies","volume":"5","author":"Katial","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib15","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01700-2021","article-title":"Is tezepelumab more than just an anti-eosinophil drug?","volume":"59","author":"Adatia","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib18","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody","volume":"341","author":"Milgrom","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib19","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/CS20190281","article-title":"New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis","volume":"137","author":"Striz","year":"2023","journal-title":"Clin. Sci."},{"key":"10.1016\/j.rmed.2024.107766_bib21","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/all.15884","article-title":"Eosinophils\u2014from cradle to grave","volume":"78","author":"Jesenak","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the Spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Brusselle","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib25","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1513\/AnnalsATS.201403-118AW","article-title":"Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease","volume":"11","author":"Brusselle","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2024.107766_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/19420862.2017.1392425","article-title":"Personalized medicine with biologics for severe type 2 asthma: current status and future prospects","volume":"10","author":"Godar","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.rmed.2024.107766_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/1744666X.2016.1216316","article-title":"Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma \u2013 an update","volume":"13","author":"Walsh","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2222.2009.03298.x","article-title":"Intrinsic asthma: not so different from allergic asthma but driven by superantigens?","volume":"39","author":"Barnes","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.rmed.2024.107766_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000447692","article-title":"A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma","volume":"170","author":"Bagnasco","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1165\/rcmb.4838","article-title":"Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9","volume":"27","author":"Whittaker","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2024.107766_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/toxins12030176","article-title":"Allergy\u2014a new role for T cell superantigens of Staphylococcus aureus?","volume":"12","author":"Abdurrahman","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.rmed.2024.107766_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2019","article-title":"Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge","volume":"55","author":"Bachert","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease \u2014 new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2024.107766_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri2254","article-title":"Immunology of asthma and chronic obstructive pulmonary disease","volume":"8","author":"Barnes","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaci.2012.04.019","article-title":"Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin","volume":"130","author":"Nagarkar","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.806391","article-title":"Role of Th17 cytokines in airway remodeling in asthma and therapy perspectives","volume":"3","author":"Margelidon-Cozzolino","year":"2022","journal-title":"Front. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2004.10.036","article-title":"Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-\u03b3-inducible protein 10 expression in asthmatic airway mucosa","volume":"115","author":"Fukakusa","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/thorax.57.3.231","article-title":"Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants","volume":"57","author":"Anees","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/all.13985","article-title":"Mechanisms and therapeutic strategies for non\u2010T2 asthma","volume":"75","author":"Sze","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma-present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.it.2015.01.005","article-title":"Lung ILC2s link innate and adaptive responses in allergic inflammation","volume":"36","author":"Martinez-Gonzalez","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107766_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.pupt.2010.06.006","article-title":"Biomarkers in asthma and allergic rhinitis","volume":"23","author":"Diamant","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2024.107766_bib51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","article-title":"Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes","volume":"203","author":"Wenzel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib54","article-title":"Asthma","volume":"1","author":"Holgate","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.rmed.2024.107766_bib55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fped.2017.00162","article-title":"Oxidative stress and bronchial asthma in children-causes or consequences?","volume":"5","author":"Jesenak","year":"2017","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.rmed.2024.107766_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MCP.0000000000000632","article-title":"Ecological interactions in asthma","volume":"26","author":"Kozik","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/ACI.0000000000000525","article-title":"Outcome measures to be considered on asthma in elderly","volume":"19","author":"Gonz\u00e1lez-D\u00edaz","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCP.0000000000000650","article-title":"Editorial: asthma: a modifiable disease on a crossroad","volume":"26","author":"Diamant","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib59","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.2500\/aap.2021.42.200100","article-title":"Applying personalized medicine to adult severe asthma","volume":"42","author":"Tiotiu","year":"2021","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.rmed.2024.107766_bib60","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5694\/mja2.51464","article-title":"Treatable traits in asthma: moving beyond diagnostic labels","volume":"216","author":"McDonald","year":"2022","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.rmed.2024.107766_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaip.2022.09.034","article-title":"Diagnosis and assessment of the asthmas","volume":"11","author":"Pavord","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib63","first-page":"1089","article-title":"Metabolic pathways in immune senescence and inflammaging: novel therapeutic strategy for chronic inflammatory lung diseases","volume":"79","author":"Roth-Walter","year":"2024","journal-title":"An EAACI position paper from the Task Force for Immunopharmacology, Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/ACI.0b013e3283630ca5","article-title":"Molecular profile clustering of IgE responses and potential implications for specific immunotherapy","volume":"13","author":"Matricardi","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11882-011-0217-4","article-title":"Severe asthma with fungal sensitization","volume":"11","author":"Agarwal","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.rmed.2024.107766_bib66","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/all.13165","article-title":"Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy","volume":"72","author":"Terl","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.anai.2017.09.058","article-title":"Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma","volume":"119","author":"Blaiss","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European respiratory society\/American thoracic society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","article-title":"Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion","volume":"10","author":"Buhl","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib70","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1183\/13993003.00436-2016","article-title":"What is asthma?COPD overlap syndrome? Towards a consensus definition from a round table discussion","volume":"48","author":"Sin","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.chest.2021.09.036","article-title":"Asthma-COPD overlap: what are the important questions?","volume":"161","author":"Leung","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2024.107766_bib72","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jaci.2011.12.979","article-title":"Asthma outcomes: biomarkers","volume":"129","author":"Szefler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE NO and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib76","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/all.14253","article-title":"Blood eosinophils: in quest of a Holy Grail for personalized asthma treatment with biologicals","volume":"75","author":"Jesenak","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1399-3038.1996.tb00389.x","article-title":"Impact of treatment on bronchial hyperresponsiveness","volume":"7","author":"De Jongste","year":"1996","journal-title":"Pediatr. Allergy Immunol. Suppl."},{"key":"10.1016\/j.rmed.2024.107766_bib78","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1378\/chest.119.5.1322","article-title":"Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients","volume":"119","author":"Silkoff","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2024.107766_bib79","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/thorax.57.10.889","article-title":"Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma","volume":"57","author":"Kharitonov","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rmed.2004.06.007","article-title":"Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma","volume":"99","author":"Nguyen","year":"2005","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib82","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.anai.2020.04.011","article-title":"Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma","volume":"125","author":"Lugogo","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib83","unstructured":"SPC of Particular Medicaments, Local\/national Guideline, ((n.d.))."},{"key":"10.1016\/j.rmed.2024.107766_bib84","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1513\/AnnalsATS.201309-307AW","article-title":"Clinical heterogeneity in the severe asthma research program","volume":"10","author":"Moore","year":"2013","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2024.107766_bib85","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00900-2019","article-title":"ERS\/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions","volume":"54","author":"Bourdin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","article-title":"Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma","volume":"74","author":"Lommatzsch","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/cea.13057","article-title":"Blood eosinophils: the forgotten man of inhaled steroid dose titration","volume":"48","author":"Jabbal","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib90","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib91","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.5415\/apallergy.2021.11.e30","article-title":"Eosinophil-mediated inflammation in the absence of eosinophilia","volume":"11","author":"Miyabe","year":"2021","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib92","first-page":"609","article-title":"Emerging biologics in severe asthma","volume":"36","author":"Pavord","year":"2016","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2024.107766_bib93","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.2147\/COPD.S149382","article-title":"Smoking history and emphysema in asthma-COPD overlap","volume":"12","author":"Kurashima","year":"2017","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.rmed.2024.107766_bib94","article-title":"Prediction of COPD risk accounting for time-varying smoking exposures","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2024.107766_bib95","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1183\/09031936.00180313","article-title":"Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement","volume":"43","author":"Vandenplas","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib96","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1165\/rcmb.2016-0017PS","article-title":"Mechanisms of asthma in obesity pleiotropic aspects of obesity produce distinct asthma phenotypes","volume":"54","author":"Dixon","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.rmed.2024.107766_bib97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM198902023200502","article-title":"Association of asthma with serum IgE levels and skin-test reactivity to allergens","volume":"320","author":"Burrows","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib98","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaip.2014.09.004","article-title":"The allergic asthma phenotype","volume":"2","author":"Schatz","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib99","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jaci.2012.05.053","article-title":"Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever","volume":"130","author":"Hatzler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/09031936.06.00074705","article-title":"The link between fungi and severe asthma: a summary of the evidence","volume":"27","author":"Denning","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib101","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/all.13072","article-title":"Allergy in severe asthma","volume":"72","author":"DelGiacco","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib102","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.jaci.2019.01.018","article-title":"Nonatopic severe asthma might still be atopic: sensitization toward Staphylococcus aureus enterotoxins","volume":"143","author":"Schreiber","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib103","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2015.01.016","article-title":"Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33","volume":"136","author":"Castanhinha","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib104","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01193-2022","article-title":"Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma","volume":"61","author":"Gauvreau","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib105","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-017-0810-5","article-title":"Overlapping effects of new monoclonal antibodies for severe asthma","volume":"77","author":"Domingo","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2024.107766_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212561","article-title":"Severe refractory asthma: current treatment options and ongoing research","volume":"7","author":"Menzella","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.rmed.2024.107766_bib107","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/iid3.233","article-title":"Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma","volume":"6","author":"Oishi","year":"2018","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.rmed.2024.107766_bib108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rmed.2018.07.006","article-title":"Towards precision medicine in severe asthma: treatment algorithms based on treatable traits","volume":"142","author":"Papaioannou","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib109","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/all.14256","article-title":"The evolving algorithm of biological selection in severe asthma","volume":"75","author":"Papadopoulos","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.18176\/jiaci.0398","article-title":"Selection of biologics in severe asthma: a multifaceted algorithm","volume":"29","author":"D\u00e1vila","year":"2019","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.alit.2019.01.004","article-title":"Biological treatments for severe asthma: a major advance in asthma care","volume":"68","author":"Busse","year":"2019","journal-title":"Allergol. Int."},{"key":"10.1016\/j.rmed.2024.107766_bib112","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaip.2022.01.040","article-title":"Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma","volume":"10","author":"Chan","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib113","first-page":"A4525","article-title":"Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the international severe asthma registry (ISAR)","volume":"201","author":"Perez-de-Llano","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.1007593","article-title":"Uncontrolled severe T2 asthma: which biological to choose? A biomarker-based approach","volume":"3","author":"L\u00f3pez-Vi\u00f1a","year":"2022","journal-title":"Front. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0042-1743290","article-title":"FeNO in asthma","volume":"43","author":"Loewenthal","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107766_bib116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1067\/mai.2001.117175","article-title":"Basophil recruitment and IL-4 production during human allergen-induced late asthma","volume":"108","author":"Nouri-Aria","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib117","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaci.2016.03.010","article-title":"Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis - PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy","volume":"137","author":"Muraro","year":"2016","journal-title":"Asthma & Immunology, J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib118","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107766_bib119","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JAA.S444693","article-title":"Real-World effectiveness of mepolizumab in patients with allergic and non-allergic asthma","volume":"17","author":"Silver","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib121","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jaip.2017.10.025","article-title":"Anti-IgE or anti-IL5: that is the question","volume":"6","author":"Israel","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13223-020-00479-1","article-title":"Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry","volume":"16","author":"Van\u00edk","year":"2020","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib123","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib124","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/biomedicines9040348","article-title":"Immunological aspects related to viral infections in severe asthma and the role of omalizumab","volume":"9","author":"Menzella","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.rmed.2024.107766_bib125","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2019.01.016","article-title":"New insights into the utility of omalizumab","volume":"143","author":"Cardet","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib126","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (Anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib127","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib128","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12890-016-0230-4","article-title":"Periostin levels and eosinophilic inflammation in poorly-controlled asthma","volume":"16","author":"Simpson","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaip.2020.11.015","article-title":"Managing T2-high severe asthma in HIV-infected patients","volume":"9","author":"Terl","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib131","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib132","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib133","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib134","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"DESTINATION study investigators, Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib135","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib136","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","article-title":"Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study","volume":"40","author":"Menzies-Gow","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2024.107766_bib137","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1016\/j.jaip.2021.07.045","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy","volume":"9","author":"Corren","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib138","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00528-2020","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Hinks","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib139","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib140","doi-asserted-by":"crossref","first-page":"AB152","DOI":"10.1016\/j.jaci.2021.12.510","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with respiratory comorbidities: results from the phase 3 NAVIGATOR study","volume":"149","author":"Carr","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21053\/ceo.2017.01606","article-title":"Samter's triad: state of the art","volume":"11","author":"Kim","year":"2018","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"10.1016\/j.rmed.2024.107766_bib142","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2024.107766_bib143","first-page":"1","article-title":"British guideline on the management of asthma","volume":"69","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib144","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jaip.2019.03.010","article-title":"Controversies in allergy: should severe asthma with eosinophilic phenotype always Be treated with anti-IL-5 therapies","volume":"7","author":"Pavord","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2024.107766_bib145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real\u2010world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta\u2010analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib146","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"NOTUS study investigators, dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib147","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.anai.2021.08.004","article-title":"Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils","volume":"128","author":"Lawrence","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib148","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.anai.2022.01.024","article-title":"A rational approach to compare and select biologic therapeutics in asthma","volume":"128","author":"Wang","year":"2022","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.rmed.2024.107766_bib150","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.rmed.2024.107766_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0949","article-title":"Positioning of tezepelumab in severe asthma","volume":"34","author":"Miralles-L\u00f3pez","year":"2024","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib152","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaci.2018.06.008","article-title":"Paucigranulocytic asthma: uncoupling of airway obstruction from inflammation","volume":"143","author":"Tliba","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib153","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1152\/japplphysiol.00329.2007","article-title":"Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation","volume":"104","author":"Sorkness","year":"2008","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.rmed.2024.107766_bib154","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02202-2022","article-title":"Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond","volume":"61","author":"Corren","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2024.107766_bib155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MCP.0000000000000927","article-title":"Bronchial thermoplasty for the treatment of severe persistent asthma","volume":"29","author":"Rodriguez","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib156","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107766_bib157","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107766_bib158","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cea.13809","article-title":"Switching between biologics in severe asthma patients. When the first choice is not proven to be the best","volume":"51","author":"Papaioannou","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib159","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/resp.14377","article-title":"Choosing and switching biological agents in severe asthma","volume":"27","author":"Adrish","year":"2022","journal-title":"Respirol. Carlton Vic"},{"key":"10.1016\/j.rmed.2024.107766_bib160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/arm92020014","article-title":"Advancing care in severe asthma: the art of switching biologics","volume":"92","author":"Dragonieri","year":"2024","journal-title":"Adv. Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib162","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/jcm12051836","article-title":"Benralizumab efficacy in late non-responders to mepolizumab and variables associated with occurrence of switching: a real-word perspective","volume":"12","author":"Caminati","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib163","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.3390\/ijms24119563","article-title":"Switching biological therapies in severe asthma","volume":"24","author":"Scioscia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.rmed.2024.107766_bib164","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma","volume":"19","author":"Otten","year":"2023","journal-title":"Considerations in clinical decision making, Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib165","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib166","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.06.004","article-title":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility","volume":"154","author":"Humbert","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2024.107766_bib167","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib168","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/all.14693","article-title":"Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma","volume":"76","author":"Kavanagh","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib169","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/biomedicines9121822","article-title":"Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: a real-life experience from southern Italy","volume":"9","author":"Pelaia","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.rmed.2024.107766_bib170","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/JAA.S358705","article-title":"Effectiveness of switching to benralizumab in severe refractory eosinophilic asthma","volume":"15","author":"G\u00f3mez-Bastero Fern\u00e1ndez","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2024.107766_bib171","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anai.2019.06.013","article-title":"Combination biologic therapy for severe persistent asthma","volume":"123","author":"Ortega","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2024.107766_bib172","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2018.08.064","article-title":"Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP\/IL13 bispecific antibodies","volume":"504","author":"Venkataramani","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.rmed.2024.107766_bib173","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","article-title":"A bispecific antibody strategy to target multiple type 2 cytokines in asthma","volume":"142","author":"Godar","year":"2018","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124002415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124002415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T22:33:04Z","timestamp":1732314784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124002415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":173,"alternative-id":["S0954611124002415"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107766","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing the right biologic treatment for individual patients with severe asthma \u2013 Lessons learnt from Picasso","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107766"}}